NEW YORK (GenomeWeb) – VolitionRx today announced a collaboration with ImmuneHealth on a pilot study to asses the feasibility of VolitionRx's technology for detecting prostate cancer. 

In the study, which was initiated today, ImmuneHealth, a Belgian contract research organization, will use VolitionRx's NuQ assays to analyze 120 blood samples from patients across four Belgian hospitals. Four groups of patients will assessed — those with aggressive prostate cancer; those with indolent prostate cancer; those with prostate hyperplasia; and negative controls. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.